Used in research and development for targeted therapies in neurodegenerative diseases, particularly Parkinson’s disease. Binds selectively to aggregated forms of alpha-synuclein, a protein implicated in the progression of Parkinson’s, helping to prevent or slow the spread of pathological protein aggregates in the brain. Investigated in clinical trials for its potential to modify disease progression by promoting clearance of toxic alpha-synuclein through immunotherapy mechanisms. Also serves as a reference standard in immunoassays and biomarker studies to measure target engagement and therapeutic efficacy in central nervous system disorders.